Business Context and Reporting Period
This Form 8-K filing by Longeveron Inc. (LGVN) reports corporate governance events occurring on March 3 and March 4, 2026. The company is incorporated in Delaware and listed on The Nasdaq Capital Market. The report addresses a temporary non-compliance with Nasdaq listing rules regarding the composition of the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and regulatory compliance rather than financial performance.
Material Changes
- Board Resignation: Mr. Richard Kender resigned from the Board of Directors and Audit Committee effective March 3, 2026. The resignation was due to his new role as Executive Chairman and Interim CEO of Seres Therapeutics, Inc., and not due to any disagreement with Longeveron.
- Listing Non-Compliance: The resignation caused the company to temporarily fail to meet Nasdaq Listing Rule 5605(c)(2)(A), which requires at least three independent directors on the Audit Committee and at least one audit committee financial expert.
- Committee Appointment: On March 4, 2026, the Board appointed existing member Dr. Roger Hajjar to the Audit Committee to restore the required number of independent members.
Outlook, Risks, and Contingencies
Remediation Plan: The company currently lacks an audit committee financial expert. Management plans to appoint or submit for stockholder election a director who qualifies as both "independent" and an "audit committee financial expert." This must occur by the earlier of the next annual shareholders meeting or within the 180-day cure period provided by Nasdaq Listing Rule 5605(c)(4).
Risk: Failure to appoint a qualified financial expert within the cure period could result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the date of the next annual shareholders meeting to determine the deadline for appointing a financial expert.
- Confirm the status of the 180-day cure period timeline relative to the March 4, 2026 notification date.
- Monitor future filings for the appointment of a new director with audit committee financial expert qualifications.
- Review the company's proxy statement for details on the upcoming election of directors.